


PHARMACEUTICAL 2023

AbCellera Biologics Inc. Rank 45 of 446










RealRate





The relative strengths and weaknesses of AbCellera Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AbCellera Biologics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 83% points. The greatest weakness of AbCellera Biologics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 203% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,025,491
Cost of Goods Sold	0
Intangible Assets	179,308
Liabilities, Current	118,320
Liabilities, Non-Current	189,310
Other Assets	118,853
Other Compr. Net Income	-1,671
Other Expenses	186,129
Other Liabilities	0
Other Net Income	22,588
Other Revenues	485,424
Property and Equipment	217,255
Research and Development	107,879
Selling, General and Administrative Expense	55,485

Output Variable	Value in 1000 USD
Assets	1,540,907
Liabilities	307,630
Expenses	349,493
Revenues	485,424
Stockholders Equity	1,233,277
Net Income	158,519
Comprehensive Net Income	157,684
Economic Capital Ratio	247%

